A team of researchers led by HHMI Investigator Michael Rosen has captured the most detailed images yet of the molecules in synthetic chromatin condensates — droplet-like structures of compacted DNA.

Dewpoint Therapeutics selects a development candidate for its MYC programme: Boston Saturday, February 14, 2026, 18:00 Hrs [IST] Dewpoint Therapeutics Inc, a biotechnology company ...

Dewpoint Therapeutics, Inc., a biotechnology company pioneering condensate-modulating therapeutics, today announced the ...

Genetic engineers can design and assemble sophisticated gene circuits to program cells with new functions, but important signaling molecules can become diluted as these cells grow and divide, causing ...

Dewpoint Therapeutics doses first patient in phase 1a/2a clinical trial of DPTX3186 to treat advanced solid tumours: Boston Monday, February 9, 2026, 18:00 Hrs [IST] Dewpoint Ther ...